|
1）Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on manage-ment of paraproteinemic demyelinating neuro-pathies. Report of a Joint Task Force of the Euro-pean Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peri-pher Nerv Syst. 2010; 15: 185-95
|
|
|
|
|
2）Nobile-Orazio E, Gallia F, Terenghi F, et al. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuro-pathies? J Neurol Sci. 2008; 266: 156-63
|
|
|
|
|
3）Latov N. Pathogenesis and therapy of neuro-pathies associated with monoclonal gammopathies. Ann Neurol. 1995; 37: S32-42
|
|
|
|
|
|
4）Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relation-ship to immune therapies. Brain. 2000; 123: 710-7
|
|
|
|
|
|
5）Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008; 4: 557-67
|
|
|
|
|
|
6）Luigetti M, Frisullo G, Laurenti L, et al. Light chain deposition in peripheral nerve as a cause of mononeuritis multiplex in Waldenstroms macroglobulinaemia. J Neurol Sci. 2010; 291: 89-91
|
|
|
|
|
|
7）Luigetti M, Madia F, Conte A, et al. Neuropathy with predominant small fiber involvement associated with abnormal anti-MAG titer. Intern Med. 2010; 49: 2627-9
|
|
|
|
|
8）Luigetti M, Conte A, Montano N, et al. Clinical and pathological heterogeneity in a series of 31 patients with IgM-related neuropathy. J Neurol Sci. 2012; 319: 75-80
|
|
|
|
|
|
9）Kawagashira Y, Kondo N, Atsuta N, et al. IgM MGUS anti-MAG neuropathy with predominant muscle weakness and extensive muscle atrophy. Muscle Nerve. 2010; 42: 433-5
|
|
|
|
|
|
10）Kuijf ML, Eurelings M, Tio-Gillen AP, et al. Detection of anti-MAG antibodies in polyneuro-pathy associated with IgM monoclonal gammopathy. Neurology. 2009; 73: 688-95
|
|
|
|
|
|
11）Monaco S, Bonetti B, Ferrari S, et al. Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med. 1990; 322: 649-52
|
|
|
|
|
|
12）Lombardi R, Erne B, Lauria G, et al. IgM deposits on skin nerves in anti-myelin-associated glyco-protein neuropathy. Ann Neurol. 2005; 57: 180-7
|
|
|
|
|
|
13）Stalder AK, Erne B, Reimann R, et al. Immunoglobulin M deposition in cutaneous nerves of anti-myelin-associated glycoprotein polyneuropathy patients correlates with axonal degeneration. J Neuropathol Exp Neurol. 2009; 68: 148-58
|
|
|
|
|
|
14）Willison HJ, Trapp BD, Bacher JD, et al. Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. Muscle Nerve. 1988; 11: 1169-76
|
|
|
|
|
|
15）Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol. 1993; 33: 502-6
|
|
|
|
|
|
16）Ilyas AA, Gu Y, Dalakas MC, et al. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol. 2008; 193: 87-93
|
|
|
|
|
|
17）Hellqvist E, Kvarnstrom M, Soderberg A, et al. Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undeter-mined significance of immunoglobulin M isotype: aberrant triggering of a patients T cells. Haemato-logica. 2010; 95: 627-36
|
|
|
|
|
|
18）Kawagashira Y, Koike H, Tomita M, et al. Morphological progression of myelin abnormal-ities in IgM-monoclonal gammopathy of undeter-mined significance anti-myelin-associated glyco-protein neuropathy. J Neuropathol Exp Neurol. 2010; 69: 1143-57
|
|
|
|
|
|
19）Vallat JM, Tabaraud F, Sindou P, et al. Myelin widenings and MGUS-IgA: an immunoelectron microscopic study. Ann Neurol. 2000; 47: 808-11
|
|
|
|
|
|
20）Vallat JM, Magy L, Sindou P, et al. IgG neuro-pathy: an immunoelectron microscopic study. J Neuropathol Exp Neurol. 2005; 64: 386-90
|
|
|
|
|
|
21）Kosmidis ML, Dalakas MC. Practical consid-erations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 2010; 3: 93-105
|
|
|
|
|
|
22）Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuro-pathy. Neurology. 2006; 66: 742-4
|
|
|
|
|
|
23）Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003; 74: 485-9
|
|
|
|
|
|
24）Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve. 2003; 7: 611-5
|
|
|
|
|
|
25）Benedetti L, Briani C, Grandis M, et al. Predictors of response to rituximab in patients with neuro-pathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst. 2007; 12: 102-7
|
|
|
|
|
|
26）Niermeijer JM, Eurelings M, Lokhorst HL, et al. Rituximab for polyneuropathy with IgM mono-clonal gammopathy. J Neurol Neurosurg Psychia-try. 2009; 80: 1036-9
|
|
|
|
|
|
27）Broglio L, Lauria G. Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve. 2005; 32: 378-9
|
|
|
|
|
|
28）Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelina-ting neuropathy. Ann Neurol. 2009; 65: 286-93
|
|
|
|
|
|
29）Benedetti L, Briani C, Franciotta D, et al. Long-term effect of rituximab in anti-mag polyneuro-pathy. Neurology. 2008; 71: 1742-4
|
|
|
|
|
|
30）Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009; 113: 4834-40
|
|
|
|
|